Los puntos clave no están disponibles para este artículo en este momento.
Canagliflozin lowered RT(G) and increased UGE, improved glycemic control and beta-cell function in rodent models of T2DM, and reduced body weight gain in rodent models of obesity.
Liang et al. (Wed,) studied this question.